Patent US3419071A successfully refreshed from Google Patents.
EP0131150A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Purification and characterization of a fibroblast growth factor
Assignee: Merck and Co Inc
•
Filing: 1984-06-05
•
Granted: —
•
Expires: 2004-06-05
Abstract
Abstract @ Acidic brain fibroblast growth factor isolated from bovine brain, is purified by the sequence of steps of: 1) extraction and differential salt precipitation from the source tissue; 2) ion exchange; 3) gel filtration; 4) ion exchange; 5) isoelectric focusing; 6) hydrophobic reverse phase chromatography. The product is useful in the promotion of cell division (mitogenesis) such as in the promotion of wound healing.
Inventors
- 👤 Kenneth A. Thomas, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 05:21
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/50; C07K14/501; A; A61; A61P; A61P43/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/839
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
24 words
An acidic brain fibroblast growth factor in substantially pure form with molecular mass of 16,600 or 16,800 daltons and an amino acid composition of:
Claim 2
Dependent Claim
24 words
An acidic brain fibroblast growth factor in substantially pure form with molecular mass of 16,600 or 16,800 daltons and an amino acid composition of:
Claim 3
Dependent Claim
15 words
. 2. The acidic brain fibroblast growth factor of Claim 1, isolated from bovine brain.
Claim 4
Dependent Claim
49 words
A process for the isolation of acidic brain fibroblast growth factor in substantially pure form which comprises the sequence of steps of: 1) extraction and differential salt precipitation from the source tissue; 2) ion exchange; 3) gel filtration; 4) ion exchange; 5) isoelectric focusing; 6) hydrophobic reverse phase chromatography.
Claim 5
Dependent Claim
49 words
A process for the isolation of acidic brain fibroblast growth factor in substantially pure form which comprises the sequence of steps of: 1) extraction and differential salt precipitation from the source tissue; 2) ion exchange; 3) gel filtration; 4) ion exchange; 5) isoelectric focusing; 6) hydrophobic reverse phase chromatography.
Claim 6
Dependent Claim
11 words
The process of Claim 3 for the isolation from bovine brain.
Claim 7
Dependent Claim
185 words
The process of Claim 3 wherein: 1) The extraction and differential salt precipitation is accomplished by sequential treatments with 0.15M ammonium sulfate at pH 4.5; 1.52M ammonium sulfate at pH 6.75; and 3.41M ammonium sulfate at pH 6.75 followed by dialysis and lyophilization of the high salt precipitate; 2) the ion exchange comprises batch adsorption on carboxymethyl-Sephadex (Pharmacia) resin at pH 6 followed by sequential elution with 0.1M sodium phosphate buffer containing 0.15M and 0.60M sodium chloride followed by dialysis and lyophilization of the 0.60M sodium chloride fraction, 3) gel filtration on a Sephadex G-75 (Pharmacia) column by elution with 0.1M ammonium bicarbonate, pH 8.5 followed by lyophilization of the pooled high activity fractions; 4) ion exchange on a carboxymethyl cellulose column loaded in 0.1M ammonium formate, pH 6.0 and eluted with 0.2M and 0.6M ammonium formate, pH 6.0, in sequence followed by lyophilization of the active pool; 5) isoelectric focusing is in Ultrodex (LKB, Gaithersburg, Maryland); and 6) hydrophobic reverse phase high performance liquid chromatographic purification of the acidic mitogen is on Vydac C 4 silica based HPLC column (The Separations Group, Hesperia, California).
Claim 8
Dependent Claim
11 words
The process of Claim 5 for the isolation from bovine brain
Claim 9
Dependent Claim
23 words
A pharmaceutical growth promoting composition comprising a pharmaceutical carrier and an effective growth promoting amount of the fibroblast growth factor of Claim 1.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.